<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03025477</url>
  </required_header>
  <id_info>
    <org_study_id>RVT_2015_2</org_study_id>
    <nct_id>NCT03025477</nct_id>
  </id_info>
  <brief_title>Two Therapeutic Strategies in First-line in Patients With Epithelial Advanced Ovarian Cancer</brief_title>
  <acronym>CHIMOVIP</acronym>
  <official_title>Randomized Study Assessing Two Strategies of First Line: a Strategy With Intraperitoneal Chemotherapy and a Strategy With Total Intravenous Strategy, in Patients With Epithelial Advanced Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Hospitalier Diaconesses Croix Saint-Simon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GERCOR - Multidisciplinary Oncology Cooperative Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Groupe Hospitalier Diaconesses Croix Saint-Simon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      CHIMOVIP is a study to determine the best therapeutic strategy in patient with ovarian
      advanced cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized phase II study, open-label and multicentric. After initial intervention
      (debulking surgery or diagnostic surgery) patient will randomized in the study according to
      Completeness of cytoreduction (CC) score (CC0 or CC&gt;1).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Anticipated">October 2029</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological complete peritoneal response (pCR)</measure>
    <time_frame>2-year</time_frame>
    <description>Interval debulking surgery or final evaluation peritoneal surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QLQ -C30) assessment</measure>
    <time_frame>Up to 2-year (at inclusion, after 3 cycles and end of treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QLQ-OV28) assessment</measure>
    <time_frame>Up to 2-year (at inclusion, after 3 cycles and end of treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IPSS score</measure>
    <time_frame>Up to 2-year (at inclusion, after 3 cycles and end of treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with treatment-related adverse events as assessed by CTCAE version 4.03</measure>
    <time_frame>2-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival (EFS)</measure>
    <time_frame>At 5-year and 10-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate at the various surgical step</measure>
    <time_frame>Up to 2-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>At 5-year and 10-year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Ovarian Cancer, Epithelial</condition>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Initial or interval surgery associated with 6 cycles of chemotherapy in intravenous (IV) of carboplatin and paclitaxel.
The regimen of administration of the chemotherapy is as following:
Carboplatin AUC 6 - IV - Day (D) 1
Paclitaxel 80mg / m² - IV - D1, D8, D15
one cycle every 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Initial or interval surgery associated with 6 cycles of chemotherapy of cisplatin and epirubicin.
Cisplatin is administrated in intraperitoneal (IP) if no macroscopic residual tumor at the end of the intervention (initial or interval). If evidence of macroscopic residual tumor, cisplatin is administered in IV. Epirubicin is always given in IV.
Second cytoreduction surgery at mid-term of chemotherapy cycles, only in patients operable in response after 3 cycles and with persistent residual disease after initial surgery or incomplete initial staging.
The regimen of administration of the chemotherapy is as following:
Cisplatin 80mg / m² - IV or IP - D1
Epirubicin 60mg / m² - IV - D3
one Cycle every 3 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC0 - Carboplatin (IV) - Paclitaxel (IV)</intervention_name>
    <description>(6 cycles)</description>
    <arm_group_label>Control arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC0 - Cisplatin (IP) - Epirubicin (IV)</intervention_name>
    <description>(6 cycles)</description>
    <arm_group_label>Experimental arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC&gt;0 - Carboplatin (IV)- Paclitaxel (IV)</intervention_name>
    <description>carboplatin (IV) - paclitaxel (IV) (3 cycles)
Interval surgery
Carboplatin (IV) - paclitaxel (IV) (3 cycles)</description>
    <arm_group_label>Control arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC&gt;0 - Cisplatin (IP/IV)- Epirubicin (IV)</intervention_name>
    <description>Cisplatin (IV) - Epirubicin (IV) (3 cycles)
Interval surgery :
if CC0: Cisplatin (IP) - Epirubicin (IV) (3 cycles)
if CC&gt;0 Cisplatin (IV)- Epirubicin (IV) (3 cycles)</description>
    <arm_group_label>Experimental arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed advanced (FIGO stage III or IV) invasive epithelial ovarian
             cancer, primary peritoneal cancer, or fallopian-tube cancer. Pleural cytology has to
             be performed in patients with pleural effusion.

          -  Initial intervention : debulking surgery or diagnostic surgery in the 3 weeks before
             inclusion

          -  Age ≥18 and &lt; 75 years old.

          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 before surgery (ECOG
             ≤ 1 and Lee score &lt; 6 in patients &gt; 70 years old).

          -  Adequate blood count (test realized in the past 14 days before inclusion) :
             neutrophils &gt; 1500/mm3, platelets &gt; 150 000/mm3.

          -  Creatinine clearance MDRD ≥ 60 mL/min

          -  Registration in a national health care system (CMU included).

          -  Signed and dated informed consent.

        Exclusion Criteria:

          -  FIGO stage IV extra-abdominal disease, with the exception of lymph nodes and pleural
             invasion.

          -  Patient having received previous chemotherapy for ovarian cancer.

          -  Left ventricular ejection fraction &lt; 50% before chemotherapy initiation

          -  Other invasive cancer in the past 5 years (baso- and spinocellular cutaneous carcinoma
             with complete resection are accepted)

          -  Concomitant administration of prophylactic phenytoin or live attenuated viral vaccines
             such as yellow fever vaccine,

          -  Patients with known hypersensitivity to any component of study drug

          -  Patients without motivation or capacity to respect study requirements and constraints

          -  Pregnancy or breast feeding women
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard VILLET, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Groupe Hospitalier Diaconessess Croix Saint Simon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Richard VILLET, MD</last_name>
    <phone>33 (0) 1 44 74 10 42</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Delphine COCHEREAU, MD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leïla BENGRINE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Leïla BENGRINE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Hospitalier Franco-Britannique</name>
      <address>
        <city>Levallois-Perret</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimery De GRAMONT, MD</last_name>
    </contact>
    <investigator>
      <last_name>Aimery De GRAMONT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Diaconesses Croix Saint Simon</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard VILLET, MD</last_name>
    </contact>
    <investigator>
      <last_name>Richard VILLET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Honorine GERVAIS, MD</last_name>
    </contact>
    <investigator>
      <last_name>Honorine GERVAIS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Delphine COCHEREAU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Poissy Saint Germain</name>
      <address>
        <city>Poissy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cyrille HUCHON, MD</last_name>
    </contact>
    <investigator>
      <last_name>Cyrille HUCHON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadia RABAN</last_name>
    </contact>
    <investigator>
      <last_name>Nadia RABAN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Senlis</name>
      <address>
        <city>Senlis</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisabeth CAROLA, MD</last_name>
    </contact>
    <investigator>
      <last_name>Elisabeth CAROLA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2016</study_first_submitted>
  <study_first_submitted_qc>January 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2017</study_first_posted>
  <last_update_submitted>November 21, 2017</last_update_submitted>
  <last_update_submitted_qc>November 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intraperitoneal</keyword>
  <keyword>Intravenous</keyword>
  <keyword>Completeness of cytoreduction score</keyword>
  <keyword>Carboplatin</keyword>
  <keyword>Epirubicin</keyword>
  <keyword>Paclitaxel</keyword>
  <keyword>Cisplatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

